Locations
Company type
Result types
Industries
Employees
Founding year
The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Close
Filter
Result configuration
Continents
Select continent
Locations
Result types
Company type
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
IRBM SPA
Pomezia, Italy
B
101-250 Employees
2009
Key takeaway
IRBM specializes in advanced drug discovery programs and highlights its expertise in Antibody Phage Display, which rapidly produces human antibody hits and therapeutic leads. This innovative approach underscores the company's commitment to developing effective therapeutics that enhance patient quality of life.
Reference
Service
Antibody Phage Display - IRBM
Phage Display single chain antibody library rapidly delivers human antibody hits and provides therapeutic leads faster than any other method.
Enthera
Milan, Italy
B
1-10 Employees
2016
Key takeaway
The company, Enthera, is developing a portfolio of first-in-class biologics, including monoclonal antibodies (mAbs) and fusion proteins, targeting the IGFBP3/TMEM219 pathway to treat autoimmune diseases. Their lead program, Ent001, has the potential to preserve pancreatic beta cells in Type 1 Diabetes and restore intestinal structure in Inflammatory Bowel Disease.
Reference
Core business
About Us – Enthera
AchilleS Vaccines
Italy
B
11-50 Employees
2017
Key takeaway
AchilleS Vaccines is focused on innovative biopharmaceutical development, particularly through its MAbCo19 project, which aims to deliver a human neutralizing monoclonal antibody for Covid-19. Their technology platform enhances the production of recombinant proteins, which may be relevant for creating bispecific antibodies.
Reference
Core business
Achilles Home - Achilles Vaccines
Looking for more accurate results?
Find the right companies for free by entering your custom query!
25M+ companies
250M+ products
Free to use
Reithera Srl
Rome, Italy
B
101-250 Employees
2005
Key takeaway
ReiThera is a biotech company specializing in the development and production of biopharmaceutical products, including genetic vaccines for major infectious diseases. Their expertise in viral vector engineering and GMP manufacturing positions them as a key player in advancing therapies through innovative gene delivery technologies.
Reference
Core business
An ideal partner for your translational research • Reithera
We develop and produce biopharmaceutical products for advanced therapies, in order to treat several serious or life-threatening diseases.
Explora Biotech
Rome, Italy
B
11-50 Employees
2006
Key takeaway
Explora Bioscience Srl is a Contract Research Organization that specializes in the development and preclinical validation of advanced-therapy medicinal products (ATMPs), including gene and cell-based therapies. Their integrated services support the testing and evaluation of innovative treatments, which can encompass bispecific antibodies as part of their comprehensive approach to next-generation therapeutics.
Reference
Service
CUSTOM SERVICES - Explora Biotech
Takis
Rome, Italy
B
11-50 Employees
2009
Key takeaway
Takis is a Biotechnology Company that focuses on developing therapeutic cancer vaccines targeting tumor antigens. With over 10 years of experience in drug discovery and a strong emphasis on innovative technologies, the company is dedicated to advancing treatments in oncology and immunology.
Reference
Core business
About us
BIOUNIVERSA srl
Fisciano, Italy
B
11-50 Employees
2009
Key takeaway
Biouniversa s.r.l. develops diagnostic and therapeutic products that leverage the biological properties of the BAG3 protein, particularly its role in modulating cell death. Specific reagents for BAG3 have shown various applications in diagnosing and treating diseases related to dysregulated cell death, such as cancer and cardiovascular conditions.
Reference
Core business
Biouniversa
HMGBiotech
Milan, Italy
B
- Employees
-
Key takeaway
HMGBiotech specializes in producing quality-controlled variants of HMGB1 and offers related products, including anti-HMGB1 monoclonal antibodies. This focus on HMGB1, a key nuclear component, highlights the company's expertise in developing reagents that may be relevant for research in areas like inflammation and cancer metastasis.
Reference
Product
anti HMGB1 monoclonal antibody - HMGBiotech Srl - HMGB1 Recombinant Human Protein
anti HMGB1 monoclonal antibody The mouse monoclonal IgG1 DPH1.1 was generated by injecting C57BL/6 mice with the 17-mer peptide P1 (KGKPDAAKKGVVKAEKS). Hybridomas were generated from splenocytes by standard techniques and tested by ELISA against the immunogen and full-length HMGB1. DPH1.1 mAb recognizes all mammalian HMGB1s, including human, mouse and rat. Does not recognize HMGB2. DPH1.1 … anti HMGB1 monoclonal antibody Read More »
Transactiva srl
Udine, Italy
B
1-10 Employees
2001
Key takeaway
Transactiva is a biotech company with expertise in molecular biology and genetic engineering. They focus on innovative products like LenEasy®, a soothing active for cosmetics, and are involved in advanced research and development.
Reference
Core business
The Company
Adaltis
Montecelio, Italy
B
251-500 Employees
1987
Key takeaway
Adaltis specializes in the development and production of in-vitro diagnostic systems and reagents, including a range of assays for diagnosing various diseases and measuring hormone responses. Notably, the company offers dedicated antibody production services, which may be relevant for the development of bispecific antibodies.
Reference
Service
Adaltis S.r.l. - Antibody Production Service / Conjugates Production Activities
Technologies which have been searched by others and may be interesting for you:
When exploring the Bispecific Antibody industry in Italy, several key considerations come into play. Regulatory frameworks are critical, as compliance with European Medicines Agency (EMA) guidelines is essential for any product development and market entry. The Italian healthcare system and reimbursement policies also significantly impact the commercialization of bispecific antibodies. Challenges such as high development costs and the complexity of manufacturing processes are prevalent in this sector. Potential investors and researchers should also be aware of the competitive landscape, which includes both established pharmaceutical companies and dynamic biotech startups focusing on innovative treatments. Opportunities exist in the growing demand for targeted therapies, particularly in oncology, where bispecific antibodies show promise in enhancing treatment efficacy. Environmental concerns related to biopharmaceutical manufacturing practices are gaining attention, urging companies to adopt sustainable practices. Additionally, the global relevance of the bispecific antibody market is notable, as Italy serves as a strategic hub for research and collaboration within the European Union. With a robust network of universities and research institutions, Italy offers a fertile ground for innovation in this field. It is essential for stakeholders to stay informed about market trends and technological advancements to navigate this evolving industry effectively.
Some interesting numbers and facts about your company results for Bispecific Antibody
| Country with most fitting companies | Italy |
| Amount of fitting manufacturers | 147 |
| Amount of suitable service providers | 113 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1987 |
| Youngest suiting company | 2017 |
Some interesting questions that has been asked about the results you have just received for Bispecific Antibody
What are related technologies to Bispecific Antibody?
Based on our calculations related technologies to Bispecific Antibody are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Which industries are mostly working on Bispecific Antibody?
The most represented industries which are working in Bispecific Antibody are Biotechnology, Other, Medical, Pharmaceuticals, IT, Software and Services
How does ensun find these Bispecific Antibody Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.